Expiration dtae: 04/2027
The dosage form
is round biconvex tablets from white to white with a yellowish tinge of color.
Composition
1 tablet contains:
Active ingredient: gimecromone - 200.00 mg.
Excipients: corn starch - 45.00 mg, gelatin - 3.00 mg, sodium lauryl sulfate - 1.00 mg, magnesium stearate - 1.00 mg.
Pharmacodynamics
A choleretic drug. Hymecromone is a derivative of coumarin. Increases the formation of bile and accelerates its excretion through the biliary tract. It has a selective antispasmodic effect on the bile ducts and the Oddi sphincter (it does not reduce peristalsis of the gastrointestinal tract and blood pressure). Reduces the stagnation of bile in the gallbladder, prevents the crystallization of cholesterol and thereby the formation of gallstones.
Pharmacokinetics
When ingested, it is easily absorbed from the digestive tract and weakly binds to plasma proteins. The maximum concentration in the blood serum is reached after -3 hours. The half-life is about 1 hour. Himecromone is excreted by the kidneys
(about 93% in the form of glucuronate, 1.4% - sulfonate, 0.3% - unchanged).
There is no data on the excretion of hymecromone in breast milk and on the passage of -5 through the placenta.
Indications
Biliary dyskinesia and Oddi sphincter hyperkinetic type, non-calculous chronic cholecystitis, cholangitis, cholelithiasis; condition after surgical interventions on the gallbladder and bile ducts. Decreased appetite, nausea, constipation, vomiting (on the background of hyposecretion of bile).
Contraindications
Hypersensitivity to the active substance or any other component of the drug.
Biliary tract obstruction, renal/hepatic insufficiency, ulcerative colitis, Crohn's disease, peptic ulcer of the stomach and duodenum, hemophilia. Children under 7 years of age.
Use during pregnancy and lactation
There is no data on the safety of using gimecromone during pregnancy and lactation. The appointment of hymecromone to pregnant women and during breastfeeding is permissible only in cases where the potential benefit to the mother exceeds the potential risk to the fetus and child.
Method of administration and dosage
Inside, 30 minutes before meals; adults - 200-400 mg (1-2 tablets) 3 times a day.
The daily dose is 1200 mg.
Children from 7 years of age - 200 mg (1 tablet) 1-3 times a day. The daily dose is 600 mg. The course of treatment is 2-3 weeks. If you miss a dose, you should take the drug as soon as possible or, if the time of the next dose is approaching, do not take the missed dose. Do not take a double dose at once.
If there is no improvement after treatment, or the symptoms worsen, or new symptoms appear, it is necessary to consult a doctor. Use the drug only according to the indications, the method of use and in the doses specified in the instructions.
Side effects
Allergic reactions are possible; diarrhea, flatulence, abdominal pain, ulceration of the gastrointestinal mucosa, headache.
If you experience side effects listed in the instructions or they worsen, or you notice any other side effects not listed in the instructions, tell your doctor.
Overdose
To date, no cases of overdose have been reported.
Drug interaction
Morphine weakens the effect of hymecromone.
When combined with metoclopramide, the effect of both drugs is weakened.
Enhances the effects of indirect anticoagulants.
If you use the above and other medications (including over-the-counter ones), consult your doctor before using the drug.
Special instructions
It does not impair the secretory function of the digestive glands and intestinal absorption processes. If symptoms of liver and/ or kidney failure appear, stop taking the drug and consult a doctor.
Influence on the ability to drive vehicles, mechanisms
The drug does not affect the ability to perform potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions (including driving vehicles, working with moving mechanisms).
Storage temperature
from 2℃ to 25℃
